%0 Journal Article
%A Döhner, Hartmut
%A Späth, Daniela
%A Saadati, Maral
%A Fiedler, Walter
%A Götze, Katharina S
%A Koller, Elisabeth
%A Westermann, Jörg
%A Vogel, Wichard
%A Heuser, Michael
%A Lübbert, Michael
%A Tischler, Hans-Joachim
%A Germing, Ulrich
%A Teichmann, Lino Lars
%A Fransecky, Lars
%A Wölfler, Albert
%A Nachbaur, David
%A Hertenstein, Bernd
%A Schroers, Roland
%A Martens, Uwe M
%A von Harsdorf, Stephanie
%A Radsak, Markus P
%A Aschauer, Gregor
%A Weißhaar, Stefanie
%A Corbacioglu, Andrea
%A Schrade, Anika
%A Gaidzik, Verena I
%A Thol, Felicitas R
%A Paschka, Peter
%A Bullinger, Lars
%A Benner, Axel
%A Döhner, Konstanze
%A Ganser, Arnold
%T Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
%J Blood
%V nn
%@ 0006-4971
%C Washington, DC
%I American Society of Hematology
%M DKFZ-2026-00049
%P nn
%D 2026
%Z epub
%X Core-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT.We report results from the randomized, open-label, phase 3 trial of intensive chemotherapy with or without the multi-kinase inhibitor dasatinib in adult patients with CBF-AML.Patients received '3+7' induction therapy, followed by 4 cycles of high-dose cytarabine; in the investigational arm, patients received dasatinib 100 mg QD on days 8-21 in induction, and on days 6-28 in consolidation cycles, followed by 12-month single-agent dasatinib 100 mg QD. Primary endpoint was event-free survival (EFS). Secondary endpoints included overall survival, relapse-free survival, and cumulative incidence of relapse.202 patients were randomly assigned to the standard arm (n=102) and to the dasatinib arm (n=100). Median age was 49 years (range, 18, 77); 94 patients had t(8;21), 108 had inv(16)/t(16;16); 58 (28.7
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41490515
%R 10.1182/blood.2025030722
%U https://inrepo02.dkfz.de/record/307552